Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

NCT06759701 · Recruiting

Last updated 2026-05-28

This study is testing whether the medication tirzepatide can help overweight or obese men with intermediate-risk prostate cancer lose weight before surgery, while monitoring for any side effects.

Status Recruiting Currently enrolling participants.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 30 people Planned (estimated).

Who can join Ages 18+ · male only

Timeline Started 2025-07 · est. completion 2028-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06759701 ↗

Description as written by the study sponsor.

The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer

Treatments tested

Tirzepatide Drug

Participants will perform weekly self-injection of tirzepatide as standard of care, following manufacturer instructions

Main thing measured	Safety and Adverse Events (AEs)
Sponsor	M.D. Anderson Cancer Center
Conditions studied	Diabetes, Prostate Cancer
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06759701 ↗